Expression and clinical significance of CA125, CA153 and CEA in nipple discharge of breast cancer patients
CA125, CA153, CEA in Breast Cancer Nipple Discharge: Significance
Abstract
Background: It is an important clinical means to identify benign and malignant breast diseases caused by nipple discharge through the detection and analysis of components in nipple discharge. This study was aimed to test the expression and clinical significance of carbohydrate antigen 125 (CA125), carbohydrate antigen 153 (CA153) and carcinoembryonic antigen (CEA) in nipple discharge of breast cancer patients.
Methods: From January 2017 to December 2018, 86 patients with invasive ductal carcinoma of the breast with nipple discharge (breast cancer group) and 50 patients with ordinary breast duct hyperplasia with nipple discharge (benign control group) were selected, and the nipple discharge and serum CA125, CA153 and CEA levels in the two groups were detected by electrochemiluminescence immunoassay.
Results: The nipple discharge and serum CA125, CA153 and CEA levels in the benign control group were significantly lower than those in the breast cancer group, and the serum CA125, CA153 and CEA levels were obviously lower than those nipple discharge levels. The expression levels of CA125, CA153 and CEA in nipple discharge in the breast cancer group had no significant difference in different age of onset and different tumor sites. The CA125, CA153 and CEA levels in nipple discharge of patients with tumor diameter n5 cm, low differentiation, high stage, metastasis, and recurrence were obviously elevated versus to those of patients with tumor diameter <5 cm, high differentiation, low stage, and no metastasis and recurrence. These levels were not significantly correlated with the expression of estrogen receptor (ER) and progesterone receptor (PR), but was significantly correlated with the expression of human epidermal growth factor receptor (HER-2) and Ki-67. The accuracy, sensitivity, and negative predictive value of nipple discharge CA125, CA153 and CEA combined tests in the diagnosis of breast cancer were markedly improved compared with serum combinations and individual tests.
Conclusion: The combination of CA125, CA153 and CEA in nipple discharge can be considered as a potential diagnostic method for breast cancer, which is an effective supplement to serological diagnosis, and can provide new ideas for the differential diagnosis of benign and malignant breast cancer with nipple discharge.
References
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Ca-Cancer J Clin 2020; 70(1): 7-30.
2. Kamali S, Bender O, Kamali GH, Aydin MT, Karatepe O, Yuney E. Diagnostic and therapeutic value of ductoscopy in nipple discharge and intraductal proliferations compared with standard methods. Breast Cancer-Tokyo 2014; 21(2): 154-61.
3. Choi JH, Ro JY. The 2020 WHO Classification of Tumors of Soft Tissue: Selected Changes and New Entities. Adv Anat Pathol 2021; 28(1): 44-58.
4. Lang JE, Kuerer HM. Breast ductal secretions: clinical features, potential uses, and possible applications. Cancer Control 2007; 14(4): 350-9.
5. Zervoudis S, Iatrakis G, Economides P, Polyzos D, Navrozoglou I. Nipple discharge screening. Womens Health 2010; 6(1): 135-51.
6. Gupta D, Mendelson EB, Karst I. Nipple Discharge: Current Clinical and Imaging Evaluation. Am J Roentgenol 2021; 216(2): 330-9.
7. Klassen CL, Hines SL, Ghosh K. Common benign breast concerns for the primary care physician. Clev Clin J Med 2019; 86(1): 57-65.
8. Dupont SC, Boughey JC, Jimenez RE, Hoskin TL, Hieken TJ. Frequency of diagnosis of cancer or high-risk lesion at operation for pathologic nipple discharge. Surgery 2015; 158(4): 988-94, 994-5.
9. Parthasarathy V, Rathnam U. Nipple discharge: an early warning sign of breast cancer. Int J Preventive Med 2012; 3(11): 810-4.
10. Dolan RT, Butler JS, Kell MR, Gorey TF, Stokes MA. Nipple discharge and the efficacy of duct cytology in evaluating breast cancer risk. Surg-J R Coll Surg E 2010; 8(5): 252-8.
11. Zhang X, Liu W, Hai T, Li F. Upgrade Rate and Predictive Factors for Breast Benign Intraductal Papilloma Diagnosed at Biopsy: A Meta-Analysis. Ann Surg Oncol 2021; 28(13): 8643-50.
12. Chen L, Zhou WB, Zhao Y, Liu XA, Ding Q, Zha XM, et al. Bloody nipple discharge is a predictor of breast cancer risk: a meta-analysis. Breast Cancer Res Tr 2012; 132(1): 9-14.
13. Kim MJ, Park BW, Lim JB, Kim HS, Kwak JY, Kim SJ, et al. Axillary lymph node metastasis: CA-15-3 and carcinoembryonic antigen concentrations in fine-needle aspirates for preoperative diagnosis in patients with breast cancer. Radiology 2010; 254(3): 691-7.
14. Li X, Dai D, Chen B, Tang H, Xie X, Wei W. Clinicopathological and Prognostic Significance of Cancer Antigen 15-3 and Carcinoembryonic Antigen in Breast Cancer: A Meta-Analysis including 12,993 Patients. Dis Markers 2018; 2018(9863092.
15. Lee JS, Park S, Park JM, Cho JH, Kim SI, Park BW. Elevated levels of preoperative CA 15-3 and CEA serum levels have independently poor prognostic significance in breast cancer. Ann Oncol 2013; 24(5): 1225-31.
16. Wu SG, He ZY, Zhou J, Sun JY, Li FY, Lin Q, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast 2014; 23(1): 88-93.
17. Duffy MJ, Evoy D, McDermott EW. CA 15-3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta 2010; 411(23-24): 1869-74.
18. Zhao S, Gai X, Wang Y, Liang W, Gao H, Zhang K, et al. Diagnostic Values of Carcinoembryonic Antigen, Cancer Antigen 15-3 and Cancer Antigen 125 Levels in Nipple Discharge. Chinese J Physiol 2015; 58(6): 385-92.
19. Sauter ER, Wagner-Mann C, Ehya H, Klein-Szanto A. Biologic markers of breast cancer in nipple aspirate fluid and nipple discharge are associated with clinical findings. Cancer Detect Prev 2007; 31(1): 50-8.
20. Oda M, Makita M, Iwaya K, Akiyama F, Kohno N, Tsuchiya B, et al. High levels of DJ-1 protein in nipple fluid of patients with breast cancer. Cancer Sci 2012; 103(6): 1172-6.
21. Zambelli A, Pappagallo G, Marchetti P. Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis. J Comp Effect Res 2020; 9(6): 423-30.
22. Petrelli F, Viale G, Cabiddu M, Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Tr 2015; 153(3): 477-91.
Copyright (c) 2023 Jun Geng, Jinli Shi, Weina Guo, Haiyan Li, Dan Yang, Yan Gao
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.